Clinical Trials
36 trialsEfficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Qilu Hospital of Shandong University
Cadonilimab Plus Nab-Paclitaxel for Recurrent or Metastatic Muscle Invasive Bladder Cancer
Tianjin Medical University Second Hospital
RADIANT
Ottawa Hospital Research Institute
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
CBPTMI
First Affiliated Hospital Xi'an Jiaotong University
RACE IT
Technical University of Munich
Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer
Zhejiang Cancer Hospital
En-Bloc Resection of Bladder Tumors
Medipol University
Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer
Hellenic GenitoUrinary Cancer Group
Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy
Hellenic GenitoUrinary Cancer Group
A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer
University of Kansas Medical Center
A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prucalopride for Postoperative Ileus in Patients Undergoing Robot-assisted Laparoscopic Radical Cystectomy
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
PEBBLE
Queen Mary University of London
ARCADIA
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Taizhou Hanzhong biomedical co. LTD
the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors
Dragonboat Biopharmaceutical Company Limited
Propranolol Adjuvant Treatment of Bladder Cancer
Central South University
ANTAGOCYST
Institut Paoli-Calmettes
CALIBER
Institute of Cancer Research, United Kingdom
Single Versus Long-term Intravesical Instillation Chemotherapy for Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma
RenJi Hospital
Paclitaxel-binding Albumin and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Third Military Medical University
Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis
Biofabri, S.L
uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer
Rigshospitalet, Denmark
Metformin and Simvastatin Use in Bladder Cancer
London Health Sciences Centre
Role of Low-intensity Shock Wave Therapy in Penile Rehabilitation Post Nerve Sparing Radical Cysto-prostatectomy
Mansoura University
OvsL
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer
National Cancer Institute (NCI)
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder
National Cancer Institute (NCI)
Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer
National Cancer Institute (NCI)
Tesetaxel for Previously Treated Patients With Bladder Cancer
Genta Incorporated
Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer
Iwate Medical University
Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer
National Cancer Institute (NCI)
APPLY
Royal Marsden NHS Foundation Trust
Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer
National Cancer Institute (NCI)